AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11764828 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rinse conditioner (NRC) for 20 s
Number of subjects: 40
Study 11764828 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA for 60 s
Number of subjects: 40
Study 11764828 — intervention group
Group type: COMPARATOR
Intervention: 17% EDTA
Number of subjects: 40
Study 8905205 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and low cholesterol diet
Number of subjects: 17
Study 8905205 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 17
Study 1915427 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg twice daily)
Number of subjects: 24
Study 1915427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (5 mg twice daily)
Number of subjects: 24
Study 1915427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 24
Study 1915427 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 24
Study 6271846 — intervention group
Group type: EXPERIMENTAL
Intervention: delta 9‐Tetrahydrocannabinol (THC)
Number of subjects: 55
Study 6271846 — intervention group
Group type: COMPARATOR
Intervention: prochlorperazine
Number of subjects: 55
Study 6271846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 31264451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Contrasting with Implementation Intentions (MCII)
Number of subjects: 346
Study 31264451 — intervention group
Group type: COMPARATOR
Intervention: Government-promoted control strategy
Number of subjects: 346
Study 31433355 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 vaginal inserts (4, 10, or 25?g)
Number of subjects: 695
Study 31433355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 27237772 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill treadmill training for 30 minutes daily for 6 weeks
Number of subjects: 32
Study 25866811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 56 mg/m2
Number of subjects: 29
Study 25866811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 74 mg/m2
Number of subjects: 29
Study 25866811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 98 mg/m2
Number of subjects: 29
Study 25866811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 74 mg/m2 for pharmacokinetics
Number of subjects: 29
Study 23889716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 10355
Study 23889716 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study 21434963 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient appliance
Number of subjects: 80
Study 21434963 — intervention group
Group type: COMPARATOR
Intervention: Hard, palatal, non-occluding appliance (Control)
Number of subjects: 80
Study 19419343 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 143
Study 19419343 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 500 mg once daily on day 1 and 250 mg once daily on days 2 through 5
Number of subjects: 143
Study 17298647 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional re-training (AR; modified visual-probe task)
Number of subjects: 106
Study 17298647 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard visual-probe task)
Number of subjects: 106
Study 14759955 — intervention group
Group type: EXPERIMENTAL
Intervention: Web intervention group with continuous access to a bioterrorism educational Web site and weekly exposure to case scenarios.
Number of subjects: 63
Study 14759955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 63
Study 11731398 — intervention group
Group type: EXPERIMENTAL
Intervention: Information pack and supplementary phone call
Number of subjects: 325
Study 11731398 — intervention group
Group type: COMPARATOR
Intervention: Information pack only
Number of subjects: 325
Study 11731398 — intervention group
Group type: EXPERIMENTAL
Intervention: Information pack and phone call
Number of subjects: 325
Study 9130735 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 24
Study 9130735 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex with MPA
Number of subjects: 24
Study 9130735 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 8195463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) coadministered with fluoxetine (20 mg/day)
Number of subjects: 18
Study 8195463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) coadministered with sertraline (50 mg/day)
Number of subjects: 18
Study 8195463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) after sertraline discontinuation
Number of subjects: 18
Study 8195463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) after fluoxetine discontinuation
Number of subjects: 18
Study 8195463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine/norfluoxetine
Number of subjects: 18
Study 8195463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline/desmethylsertraline
Number of subjects: 18
Study 3315118 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF)
Number of subjects: 0
Study 3315118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3315118 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF) in rats
Number of subjects: 0
Study 30390870 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-honey mixture (twice a day for three days)
Number of subjects: 68
Study 30390870 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 68
Study 27166794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of folic acid daily (Group 1)
Number of subjects: 460
Study 27166794 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of folic acid daily (Group 2)
Number of subjects: 460
Study 25594129 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination blue light therapy (n = 26)
Number of subjects: 41
Study 25594129 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 15)
Number of subjects: 41
Study 23870722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g/day n-3 PUFAs
Number of subjects: 15
Study 23870722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21691804 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α blockers (Infliximab and Adalimumab)
Number of subjects: 1226
Study 21691804 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α blockers
Number of subjects: 1226
Study 21691804 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo or other drugs)
Number of subjects: 1226
Study 18378871 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms assessment using the State Trait Anxiety Inventory at baseline, 6, and 18 months
Number of subjects: 638
Study 18378871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinomial logistic regression analyses
Number of subjects: 638
Study 18378871 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of angina and major depression, not using diuretics
Number of subjects: 638
Study 16113850 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic drugs (dipirone or diazepan)
Number of subjects: 100
Study 16113850 — intervention group
Group type: COMPARATOR
Intervention: Anti-hypertensive drug (captopril)
Number of subjects: 100
Study 12944062 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 143
Study 12944062 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (cytogenetic responders)
Number of subjects: 143
Study 12944062 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (non-responders)
Number of subjects: 143
Study 12944062 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (historical controls)
Number of subjects: 143
Study 10799197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (25 patients)
Number of subjects: 51
Study 10799197 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 patients)
Number of subjects: 51
Study 8815681 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal immunoglobulin administration
Number of subjects: 0
Study 8815681 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal anti‐CMV antibodies (MSL‐109)
Number of subjects: 0
Study 8815681 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of CMV‐specific CD8 cells
Number of subjects: 0
Study 1612492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (5 mg four times daily)
Number of subjects: 60
Study 1612492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6430142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium citrate (1.3 meq/kg body weight daily for 8 weeks)
Number of subjects: 12
Study 6430142 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (for 8 weeks)
Number of subjects: 12
Study 6430142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium citrate
Number of subjects: 12
Study 6430142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium citrate and acetate dialysate
Number of subjects: 12
Study 31753261 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental Nutrition Assistance Program participants
Number of subjects: 950
Study 31753261 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants
Number of subjects: 950
Study 31753261 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP participants
Number of subjects: 950
Study 31753261 — intervention group
Group type: COMPARATOR
Intervention: Difference-in-difference estimators comparing SNAP participants with nonparticipants
Number of subjects: 950
Study 28744993 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined implants in smokers
Number of subjects: 32
Study 28744993 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 32
Study 28744993 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 32
Study 28744993 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (smokers and non-smokers)
Number of subjects: 32
Study 26065445 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1,000 mg every 24 hours
Number of subjects: 0
Study 26065445 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg (single oral dose)
Number of subjects: 0
Study 26065445 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1,000 mg (single oral dose)
Number of subjects: 0
Study 24050419 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based diet, physical activity, and stress reduction intervention
Number of subjects: 159
Study 24050419 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 159
Study 21474700 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 29
Study 21474700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV)
Number of subjects: 29
Study 21474700 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT)
Number of subjects: 29
Study 20037644 — intervention group
Group type: EXPERIMENTAL
Intervention: FP9-TRAP vaccine
Number of subjects: 0
Study 20037644 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-TRAP vaccine
Number of subjects: 0
Study 20037644 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccination (control)
Number of subjects: 0
Study 20037644 — intervention group
Group type: EXPERIMENTAL
Intervention: FFM ME-TRAP vaccine
Number of subjects: 0
Study 16773437 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175, 210, and 250 mg/m² over 3 h every 3 weeks)
Number of subjects: 469
Study 16773437 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 expression
Number of subjects: 469
Study 16773437 — intervention group
Group type: EXPERIMENTAL
Intervention: PGP expression
Number of subjects: 469
Study 16773437 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of IL-6 and PGP
Number of subjects: 469
Study 12842680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anesthesia with i.v. cannula
Number of subjects: 119
Study 12842680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anesthesia without i.v. cannula
Number of subjects: 119
Study 12842680 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia of proparacaine 0.5% without i.v. cannula
Number of subjects: 119
Study 11085807 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,640 IU 25-HCC per week + 1 g calcium per day
Number of subjects: 58
Study 11085807 — intervention group
Group type: COMPARATOR
Intervention: 1 g calcium per day
Number of subjects: 58
Study 8775098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 8775098 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 1615177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone diproprionate (1500 micrograms day‐1)
Number of subjects: 20
Study 6377865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol b.i.d. (80, 160, 320 mg/day)
Number of subjects: 78
Study 6377865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol q.i.d. (80, 160, 320 mg/day)
Number of subjects: 78
Study 6377865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol q.d. (80, 160, 320 mg/day)
Number of subjects: 78
Study 6377865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 6377865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol b.i.d.
Number of subjects: 78
Study 6377865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol q.i.d.
Number of subjects: 78
Study 6377865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol q.d.
Number of subjects: 78
Study 30360658 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (250 μg daily)
Number of subjects: 53
Study 30360658 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 53
Study 30360658 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 53
Study 30027756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 10 weeks)
Number of subjects: 0
Study 27687441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.75 μg/kg
Number of subjects: 60
Study 27687441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 μg/kg
Number of subjects: 60
Study 27687441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 μg/kg
Number of subjects: 60
Study 24488793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cryotherapy (30 to 90 minutes)
Number of subjects: 53
Study 24488793 — intervention group
Group type: COMPARATOR
Intervention: Standardized postoperative treatment plan alone (no preoperative cryotherapy)
Number of subjects: 53
Study 22285579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ISA (n = 37, 39 lesions)
Number of subjects: 194
Study 22285579 — intervention group
Group type: COMPARATOR
Intervention: Patients without ISA (n = 157, 182 lesions)
Number of subjects: 194
Study 22285579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ISA
Number of subjects: 194
Study 22285579 — intervention group
Group type: COMPARATOR
Intervention: Patients without ISA
Number of subjects: 194
Study 20070143 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 1000 mg twice-daily
Number of subjects: 299
Study 20070143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 17663608 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 0
Study 17663608 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 0
Study 16109464 — intervention group
Group type: COMPARATOR
Intervention: Radiation Therapy (RT) alone
Number of subjects: 100
Study 16109464 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus total androgen suppression (RTHormones)
Number of subjects: 100
Study 12110494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (1000 mg/m2) on day 1 preceding cisplatin infusion, 30 mg/m2/24 h cisplatin intravenous bolus days 1-4, and 1000 mg/m2/24 h 5-FU in a 4-h infusion on days 1-4.
Number of subjects: 170
Study 12110494 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (30 mg/m2/24 h) and 5-FU in the same dosage and schedule as in arm A.
Number of subjects: 170
Study 10194886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc instruction (IVDI) with cooperative learning strategies
Number of subjects: 0
Study 8524975 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐chlorophenylpiperazine (m‐CPP, 0.08 mg/kg IV) with scopolamine (0.4 mg IV)
Number of subjects: 10
Study 8524975 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg IV)
Number of subjects: 10
Study 8524975 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.15 mg/kg IV)
Number of subjects: 10
Study 8524975 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg IV) + ondansetron (0.15 mg/kg IV)
Number of subjects: 10
Study 8524975 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 2405105 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus Leucovorin (LV)
Number of subjects: 61
Study 2405105 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus Placebo
Number of subjects: 61
Study 6101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 6
Study 6101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 6
Study 6101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg
Number of subjects: 6
Study 6101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.25 mg
Number of subjects: 6
Study 31397645 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived burden
Number of subjects: 62
Study 31397645 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater thwarted belonging
Number of subjects: 62
Study 31397645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility, cognition, and social participation
Number of subjects: 62
Study 30772853 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for pressure ulcers
Number of subjects: 0
Study 28863395 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT Group (n=17)
Number of subjects: 34
Study 28863395 — intervention group
Group type: COMPARATOR
Intervention: MTZ+AMX Group (n=17)
Number of subjects: 34
Study 25587020 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 121
Study 25587020 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 121
Study 25587020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 23502660 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 109
Study 23502660 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 109
Study 23502660 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (after crossover)
Number of subjects: 109
Study 23502660 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (after crossover)
Number of subjects: 109
Study 23502660 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (maximum dose)
Number of subjects: 109
Study 23502660 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (maximum dose)
Number of subjects: 109
Study 21539759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (30 mg/1 ml)
Number of subjects: 150
Study 21539759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (10 mg/1 ml)
Number of subjects: 150
Study 21539759 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 150
Study 19438689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser with high energy
Number of subjects: 20
Study 19438689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ablative fractional laser resurfacing and nonablative laser resurfacing
Number of subjects: 20
Study 19438689 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional laser with low energy plus nonablative resurfacing laser
Number of subjects: 20
Study 17084250 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 10, 30, 60, or 90 mg/day
Number of subjects: 174
Study 17084250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 17084250 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib plus atorvastatin
Number of subjects: 174
Study 11813226 — intervention group
Group type: EXPERIMENTAL
Intervention: Different recruitment strategies
Number of subjects: 0
Study 11813226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive methods of describing clustering
Number of subjects: 0
Study 10088980 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic counseling (intervention group)
Number of subjects: 40
Study 10088980 — intervention group
Group type: COMPARATOR
Intervention: Monitoring (control group)
Number of subjects: 40
Study 7569283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan 100 mg
Number of subjects: 10
Study 7569283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan 50 mg
Number of subjects: 10
Study 7569283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2188847 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 9
Study 2188847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7002481 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 7002481 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection with placebo
Number of subjects: 60
Study 7002481 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection with active tolmetin sodium
Number of subjects: 60